These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25342989)

  • 1. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
    Ferraro D; Zalcberg J
    Ther Adv Med Oncol; 2014 Sep; 6(5):222-8. PubMed ID: 25342989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
    Zalcberg JR
    Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fourth-line rescue treatment ripretinib of advanced small intestine gastrointestinal stromal tumors who achieved partial response: a case report.
    Liu B; Kou Y
    J Gastrointest Oncol; 2022 Jun; 13(3):1505-1513. PubMed ID: 35837161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
    Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
    Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal stromal tumor.
    Singeltary B; Ghose A; Sussman J; Choe K; Olowokure O
    J Gastrointest Oncol; 2014 Feb; 5(1):E27-9. PubMed ID: 24490049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?
    Kikuchi H; Hiramatsu Y; Kamiya K; Morita Y; Sakaguchi T; Konno H; Takeuchi H
    Transl Gastroenterol Hepatol; 2018; 3():14. PubMed ID: 29682621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine in gastrointestinal stromal tumors.
    Florou V; Trent JC; Wilky BA
    Discov Med; 2019; 28(155):267-276. PubMed ID: 32053767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib for treatment of advanced gastrointestinal stromal tumors.
    Overton LC; Heinrich MC
    Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current research and treatment for gastrointestinal stromal tumors.
    Lim KT; Tan KY
    World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State of the Art in the Treatment of Gastrointestinal Stromal Tumors.
    Garlipp B; Bruns CJ
    Gastrointest Tumors; 2014 May; 1(4):221-36. PubMed ID: 26672673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
    Wardelmann E; Büttner R; Merkelbach-Bruse S; Schildhaus HU
    Virchows Arch; 2007 Oct; 451(4):743-9. PubMed ID: 17701051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.